

REMARKS

I. STATUS OF THE CLAIMS AND FORMAL MATTERS

Claims 1-14 were pending in the present application. Claims 15 and 16 are new. Claims 15 and 16 recite that the angiodependent disease is psoriasis. Support for the new claims can be found throughout the specification and claims as originally filed. See, e.g., original claim 8. No new matter has been introduced.

In addition, Applicants wish to remind the Examiner of the Change in Power of Attorney and Correspondence Address filed August 25, 2008. Accordingly, kindly direct all communications in this application to Frommer Lawrence & Haug LLP, 745 Fifth Avenue, New York, NY 10151.

II. ELECTION OF SPECIES REQUIREMENT

The May 27, 2009 Office Communication contends that Applicants' Amendment and Response filed March 5, 2009 did not set forth a disease as required by the Restriction Requirement mailed January 5, 2009. The Examiner acknowledges that claim 2, which recited that the angiodependent disease presents a reduction of apoptosis, was noted in the Restriction Requirement mailed January 5, 2009; however, upon reconsideration, the Examiner contends that "reduction in apoptosis" is not an actual disease as required for election.

Applicants provisionally elect, *for search purposes only*, wherein the angiodependent disease is psoriasis. Claims 1-2, 5-7, and 12-16 are readable thereon.

Applicants reserve the right to file a divisional application, if necessary, to proceed with the examination of claims directed to one or more of the non-elected species.

Claim 1 is generic to all elected species. Applicants understand that, upon the allowance of a generic claim, claims to additional species will be considered, as provided by 37 C.F.R. § 1.141. Applicants also understand that the Examiner can broaden the search to include other species, e.g., upon determining that a species is allowable, or when there is a relationship among the species and/or the number of species is not too great.


CONCLUSION

Early and favorable consideration of the application on the merits, and early Allowance of the application are earnestly solicited.

The Commissioner is authorized to charge any fee occasioned by this paper, or credit any overpayment in fees, to Deposit Account No. 50-0320.

Respectfully submitted,
FROMMER LAWRENCE & HAUG LLP

By:


Sandra Kuzmich, Ph.D.

Reg. No. 46,117

Kathleen N. Ehrhard, Ph.D.

Reg. No. 55,144

Tel.: (212) 588-0800